Davis Polk advised the underwriters in connection with the SEC-registered offering of 4,166,167 shares of common stock of Cempra, Inc. The net proceeds to Cempra were approximately $93.7 million. Cempra’s common stock is listed on the NASDAQ Global Market under the symbol “CEMP.”

Based in Chapel Hill, North Carolina, Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Solithromycin (CEM-101), Cempra’s lead product candidate, is being developed initially for the treatment of community acquired bacterial pneumonia. Taksta (CEM-102), Cempra’s second product candidate, is being developed in the United States for oral treatment of acute bacterial skin and skin structure infections, and is being explored for long-term oral treatment of refractory infections in bones and joints.

The Davis Polk capital markets team included partner Richard D. Truesdell Jr., counsel Jeffrey S. Ramsay, former associate Denny Won and associate John H. Runne. The tax team included partner Michael Mollerus and associate Peter Benesch. Counsel Betty Moy Huber and associate Michael Comstock provided environmental advice. Associates Bonnie Chen and Fiona Finlay-Hunt provided intellectual property and technology advice. All members of the Davis Polk team are based in the New York office.

Copy link to share post